A recent study (BMJ 2014; 348: g2688) evaluated possible discrepancies in clinical trials dedicated to the assessment of the possible beneficial effect of cell therapy in heart diseases. To that end, they analysed 49 clinical trials, finding around 600 discrepancies in them. They concluded that, although it is difficult to completely avoid these discrepancies, it is important to try to do so, because they could influence the results. They added that they had only found 5 clinical trials, in which stem cells from bone marrow had been used for cell therapy in myocardial infarction, in which no discrepancies had been detected. In precisely these, the functional improvement found was nil.
La entrada Cell therapy effectiveness in myocardial infarction aparece primero en Observatorio de Bioética, UCV.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.